Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Cancer Diagnostics Market Value Growth And Long-Term Outlook
The cancer diagnostics market has witnessed rapid expansion in recent years. This market is projected to grow from $25.5 billion in 2025 to $28.58 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. The growth observed in the past can be attributed to factors such as increasing global cancer prevalence, heightened investments in oncology research, an expansion of hospital diagnostic infrastructure, the rising adoption of imaging-based cancer detection techniques, and improvements in laboratory automation.
The cancer diagnostics market is anticipated to experience substantial growth over the coming years. This market is projected to reach $44.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. The expansion during the forecast period can be attributed to the escalating demand for personalized cancer therapies, the rising acceptance of next-generation sequencing diagnostics, the broadening of population-wide cancer screening programs, increasing investments in AI-enabled oncology diagnostics, and continuous innovation in multi-cancer detection tests. Significant trends expected during this period include the greater adoption of molecular and companion diagnostics, the increasing integration of AI in cancer detection, the growing application of biomarker-based testing, the proliferation of high-throughput diagnostic platforms, and an enhanced focus on early cancer screening.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Diagnostics Market Demand Drivers: What’s Powering Industry Growth?
The expansion of the cancer diagnostics market is anticipated to be fueled by the growth in healthcare spending. Healthcare expenditure encompasses all financial resources allocated to healthcare services, such as medical interventions, hospital stays, pharmaceuticals, and public health programs, by governments, corporations, and individuals. The heightened need for healthcare spending stems from the growing occurrence of chronic illnesses, which necessitate prolonged and expensive treatments. Increased healthcare expenditure bolsters cancer diagnostics through promoting advanced screening technologies and widening access to services for early detection. It also elevates diagnostic precision by fostering greater investment in contemporary equipment and specialized laboratories, which facilitates prompt intervention and superior patient results. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Consequently, the uptick in healthcare spending is propelling the expansion of the cancer diagnostics market.
Cancer Diagnostics Market Segment Landscape And Growth Outlook
The cancer diagnostics market covered in this report is segmented –
1) By Products: Companion Diagnostics, Molecular Diagnostics
2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
Subsegments:
1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics,
2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics
Cancer Diagnostics Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the cancer diagnostic device market are prioritizing the creation of technology that incorporates artificial intelligence (AI), such as QAi Prostate, to achieve a competitive advantage. QAi Prostate functions as a diagnostic instrument for the detection of prostate cancer. As an illustration, in March 2023, Qritive, a Singapore-headquartered firm specializing in AI-powered diagnostic tools for pathologists, unveiled QAi Prostate. QAi Prostate stands as a sophisticated artificial intelligence (AI)-driven tool for diagnosing prostate cancer. It utilizes machine learning algorithms to accurately pinpoint and categorize both malignant and benign areas in prostate tissue samples. The device is engineered to support pathologists in detecting prostate cancer and distinguishing between malignant and benign regions in prostate tissue samples.
Cancer Diagnostics Market Key Participants And Competitive Landscape
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics
View The Full Cancer Diagnostics Market Report:
Cancer Diagnostics Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
